Literature DB >> 11566611

The IGF system and breast cancer.

D Sachdev1, D Yee.   

Abstract

The IGF system components have been implicated in breast cancer progression. IGF-I and IGF-II are mitogenic and anti-apoptotic peptides that influence the proliferation of various cell types including normal and transformed breast epithelial cells. The IGF system is a key growth regulatory pathway in breast cancer. As various components of the IGF system have been directly or indirectly implicated in breast cancer, it is essential to gain a better understanding of these in order to develop more specific therapeutic strategies for treating breast cancer.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11566611     DOI： 10.1677/erc.0.0080197

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  98 in total

1.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Authors:  Danielle B Ulanet; Dale L Ludwig; C Ronald Kahn; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

Review 2.  Minireview: Were the IGF Signaling Inhibitors All Bad?

Authors:  Heather Beckwith; Douglas Yee
Journal:  Mol Endocrinol       Date:  2015-09-14

3.  IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-.

Authors:  Yuzhe Yang; Douglas Yee
Journal:  Cancer Res       Date:  2014-03-31       Impact factor: 12.701

4.  Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.

Authors:  Chad P Garner; Yuan C Ding; Esther M John; Sue A Ingles; Olufunmilayo I Olopade; Dezheng Huo; Clement Adebamowo; Temidayo Ogundiran; Susan L Neuhausen
Journal:  Hum Genet       Date:  2008-01-22       Impact factor: 4.132

5.  Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.

Authors:  Yi Peter Hu; Sandip B Patil; Michelle Panasiewicz; Wenhui Li; Jennie Hauser; Lisa E Humphrey; Michael G Brattain
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

6.  Diabetes, diabetes treatment and breast cancer prognosis.

Authors:  Juhua Luo; Beth Virnig; Michael Hendryx; Sijin Wen; Rowan Chelebowski; Chu Chen; Tomas Rohan; Lesley Tinker; Jean Wactawski-Wende; Lawrence Lessin; Karen Margolis
Journal:  Breast Cancer Res Treat       Date:  2014-09-27       Impact factor: 4.872

7.  Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.

Authors:  Iván P Uray; Qiang Shen; Hye-Sook Seo; HeeTae Kim; William W Lamph; Reid P Bissonnette; Powel H Brown
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

Review 8.  IGF-I receptor, cell-cell adhesion, tumour development and progression.

Authors:  Loredana Mauro; Eva Surmacz
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

Review 9.  The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.

Authors:  Martin G Belinsky; Lori Rink; Kathy Q Cai; Michael F Ochs; Burton Eisenberg; Min Huang; Margaret von Mehren; Andrew K Godwin
Journal:  Cell Cycle       Date:  2008-10-07       Impact factor: 4.534

10.  Plasma IGF-1 and IGFBP-3 may be imprecise surrogates for breast concentrations: an analysis of healthy women.

Authors:  Adana A Llanos; Theodore M Brasky; Ramona G Dumitrescu; Catalin Marian; Kepher H Makambi; Bhaskar V S Kallakury; Scott L Spear; David J Perry; Rafael J Convit; Mary E Platek; Lucile L Adams-Campbell; Jo L Freudenheim; Peter G Shields
Journal:  Breast Cancer Res Treat       Date:  2013-03-02       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.